

Supplementary Online Content

Barbieri JS, St Claire K, Mostaghimi A, Albrecht J. Evaluation of clinical compendia used for Medicare Part D coverage determinations for off-label prescribing in dermatology. *JAMA Dermatol*. Published online January 23, 2019. doi:10.1001/jamadermatol.2018.5052

eTable. Inclusion of Dermatologic Treatments in Compendia Accepted by Medicare

eReferences.

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Inclusion of Dermatologic Treatments in Compendia Accepted by Medicare. The evidence grades are categorized as: A: Double-Blind Study; B: Clinical Trial ≥20 Subjects; C: Clinical Trial <20 Subjects; D: Series ≥5 Subjects; and E: Individual case reports amounting to published experience of fewer than five cases. E: etanercept, A: adalimumab, I: infliximab. AHFS: American Hospital Formulary Service Drug Information

Disease (prevalence/incidence)	Disease included in DRUGDEX?	Evidence-based treatments	Evidence grade	1st, 2nd, or 3rd line	Disease included as indication in	
					DRUGDEX	AHFS
Autoimmune progesterone dermatitis (fewer than 200 reported cases) ¹	No	Leuprolide acetate	A	1	No	No
		Tamoxifen	D	1	No	No
		Danazol	E	2	No	No
		Azathioprine	E	2	No	No
Behcet's syndrome (5 per 100,000) ²	Yes	Colchicine	A	1	Yes	No
		Sucralfate	A	1	No	No
		Dapsone	A	2	Yes	No
		Thalidomide	A	2	Yes	Yes
		Methotrexate	E	2	No	No
		Isotretinoin	E	3	No	No
		Interferon-alpha	A	3	No	No
		Cyclosporine	A	3	Yes	No
		Azathioprine	A	3	No	No
		Cyclophosphamide	A	3	Yes	No
		Chlorambucil	D	3	Yes	Yes
		Minocycline	C	3	No	No
		Penicillin	B	3	No	No
		Rebamipide	A	3	No	No
		TNF inhibitors	A	3	Yes (E, A, I) - if ocular	Yes (I), No (E,A)
		Azithromycin	D	3	No	No
		Lenalidomide	E	3	No	No
Apremilast	A	3	No	No		
Bullous Pemphigoid (4 per 100,000 person-years) ³	Yes	Tetracycline and nicotinamide	B	1	No	No
		Minocycline	C	1	No	No
		Azathioprine	B	2	Yes	No
		Mycophenolate mofetil	B	2	No	No
		Dapsone	C	2	Yes	No

		Methotrexate	C	2	Yes	No
		Intravenous Immunoglobulin	C	3	Yes	No
		Chlorambucil	C	3	No	No
		Cyclophosphamide	E	3	No	Yes
		Cyclosporine	E	3	No	No
		TNF inhibitors	E	3	Yes (E), No (A,I)	No (E,A,I)
		Rituximab	E	3	No	No
		Daclizumab	E	3	No	No
		Omalizumab	E	3	No	No
Cutaneous lupus / systemic lupus erythematosus (70 per 100,000) ⁴	Yes	Hydroxychloroquine	A	1	No	Yes
		Chloroquine	B	1	No	Yes
		Quinacrine	B	1	No	No
		Mycophenolate mofetil	B	2	Yes	No
		Methotrexate	D	2	Yes	Yes
		Azathioprine	D	2	Yes	No
		Dapsone	D	2	Yes	No
		Thalidomide	B	2	Yes	Yes
		Lenalidomide	C	2	No	No
		Acitretin	B	2	No	Yes
		Intravenous Immunoglobulin	D	3	Yes	Yes
		Cyclophosphamide	D	3	Yes	Yes
		Rituximab	E	3	Yes	No
		Belimumab	E	3	Yes	Yes
Dermatomyositis (22 per 100,000) ⁵	Yes	Hydroxychloroquine	D	1	Yes	No
		Chloroquine	D	1	No	No
		Quinacrine	E	1	No	No
		Methotrexate	A	1	Yes	Yes
		Mycophenolate mofetil	B	1	No	No
		Azathioprine	A	1	Yes	No
		Rituximab	A	2	No	No
		Intravenous Immunoglobulin	A	2	Yes	Yes
		Dapsone	E	3	No	No
		Thalidomide	E	3	No	No
		Leflunomide	E	3	No	No
		Sirolimus	E	3	No	No
		Tocilizumab	E	3	No	No
		Anakinra	D	3	No	No

		Sifalimumab	D	3	No	No
		Tofacitinib	D	3	No	No
Eosinophilic fasciitis (1.4 per 100,000) ⁶	Yes	Methotrexate	B	1	No	No
		Hydroxychloroquine	C	2	No	No
		Cyclosporine	E	2	No	No
		Cimetidine	C	2	No	No
		Azathioprine	E	3	No	No
		Chloroquine	E	3	No	No
		Infliximab	E	3	No	No
		Rituximab	E	3	No	No
		Dapsone	E	3	No	No
		Mycophenolate mofetil	E	3	No	No
		Tocilizumab	E	3	No	No
Epidermolysis bullosa acquisita (0.26 per 1,000,000 person-years) ⁷	Yes	Dapsone	D	1	No	No
		Mycophenolate mofetil	E	1	No	No
		Intravenous Immunoglobulin	D	2	Yes	No
		Colchicine	D	2	No	No
		Cyclosporine	D	2	Yes	No
		Rituximab	D	3	No	No
		Minocycline	E	3	No	No
Folliculitis decalvans (fewer than 300 cases reported) ⁸	No	Clindamycin and Rifampin	C	1	No	No
		Doxycycline	C	1	No	No
		Azithromycin	D	1	No	No
		Isotretinoin	D	2	No	No
		Dapsone	E	2	No	No
		TNF inhibitors	E	3	No (E,A,I)	No (E,A,I)
		Intravenous Immunoglobulin	E	3	No	No
Granuloma annulare (0.1-0.4% of new patients presenting to dermatologists) ⁹	No	Isotretinoin	C	1	No	No
		Acitretin	C	1	No	No
		Dapsone	C	1	Yes	No
		Hydroxychloroquine	D	2	No	No
		Fumaric acid esters	C	2	No	No
		Chlorambucil	D	2	No	No
		Tetracycline-class antibiotics (e.g. doxycycline, minocycline)	E	2	No	No
		Allopurinol	E	2	No	No
		Pentoxifylline	E	2	No	No
		Cyclosporine	E	2	Yes	No

		Methotrexate	E	2	No	No
		Hydroxyurea	E	2	No	No
		TNF inhibitors	D	2	No (E,A,I)	No (E,A,I)
		Rifampicin, ofloxacin, and minocycline	D	2	No	No
		Defibrotide	E	2	No	No
Hidradenitis suppurativa (98 per 100,000) ¹⁰	Yes	Tetracycline-class antibiotics (e.g. doxycycline, minocycline)	B	1	No	No
		Clindamycin and rifampin	B	1	No	No
		Metformin	C	2	No	No
		Acitretin	C	2	No	No
		Spirolactone	C	2	No	No
		Quinolone antibiotics	C	2	No	No
		TNF inhibitors	A	3	Yes (A [FDA], E, I)	No (E,A,I)
		Cyclosporine	D	3	No	No
Lichen myxedematosus (fewer than 50 cases reported) ¹¹	No	Melphalan	C	1	No	No
		Intravenous Immunoglobulin	C	1	No	No
		Bortezomib	D	2	No	No
		Isotretinoin	D	2	No	No
		Cyclophosphamide	E	3	No	No
		Cyclosporine	E	3	No	No
		Methotrexate	E	3	No	No
Linear IgA bullous dermatosis (1 per 1,000,000 person-years) ¹²	Yes	Dapsone	C	1	No	No
		Sulfapyridine	C	2	No	No
		Colchicine	D	2	No	No
		Doxycycline	E	2	No	No
		Methotrexate	E	3	No	No
		Mycophenolate mofetil	E	3	No	No
		Azathioprine	E	3	No	No
		Cyclosporine	E	3	No	No
		Intravenous Immunoglobulin	E	3	No	No
		Thalidomide	E	3	No	No
		Interferon-alpha	E	3	No	No
Mucous membrane pemphigoid (2 per 1,000,000 person-years) ¹³	Yes	Dapsone	C	1	Yes	No
		Tetracycline-class antibiotics (e.g. doxycycline, minocycline)	D	1	No	No
		Cyclophosphamide	C	1	Yes	No

		Mycophenolate mofetil	C	2	No	No
		Azathioprine	D	2	Yes	No
		Methotrexate	D	2	Yes	No
		Cyclosporine	D	2	No	No
		Rituximab	D	3	No	No
		Intravenous Immunoglobulin	C	3	Yes	No
		TNF inhibitors	E	3	Yes (E), No (A,I)	No (E,A,I)
		Pentoxifylline	C	3	No	No
		Colchicine	E	3	No	No
Palmoplantar pustulosis (1 per 1,000) ¹⁴	No	Isotretinoin	A	1	No	No
		Acitretin	A	1	No	No
		Cyclosporine	A	2	No	Yes
		Methotrexate	B	2	No	No
		Fumaric acid esters	B	2	No	No
Pemphigus Vulgaris (0.7 per 100,000 person-years) ³	Yes	Rituximab	A	1	Yes	Yes
		Mycophenolate mofetil	B	2	No	No
		Azathioprine	C	2	Yes	No
		Intravenous Immunoglobulin	C	2	Yes	Yes
		Cyclophosphamide	B	3	Yes	Yes
		Chlorambucil	D	3	No	No
Pityriasis rubra pilaris (0.2% of new patients presenting to dermatologists) ¹ ₅	No	Acitretin	D	1	No	No
		Isotretinoin	D	1	No	Yes
		Methotrexate	D	1	No	No
		Cyclosporine	E	2	No	No
		TNF inhibitors	D	2	No (E,A,I)	No (E,A,I)
		Ustekinumab	E	2	No	No
		Secukinumab	E	2	No	No
		Apremilast	E	2	No	No
		Intravenous Immunoglobulin	E	3	No	No
		Fumaric acid esters	E	3	No	No
Prurigo pigmentosa (fewer than 100 cases reported outside of Japan) ¹⁶	Yes	Minocycline	C	1	Yes	No
		Dapsone	C	2	No	No
		Doxycycline	E	2	No	No
		Roxithromycin	E	2	No	No
		Clarithromycin	E	2	No	No
		Isotretinoin	E	3	No	No
	Yes	Dapsone	D	1	Yes	No

Pyoderma gangrenosum (1 per 100,000 person-years) ¹⁷		Minocycline	D	1	No	No
		Sulfasalazine	D	1	No	No
		Cyclosporine	B	2	Yes	No
		TNF inhibitors	A	3	Yes (I), No (E,A)	No (E,A,I)
		Cyclophosphamide	D	3	No	Yes
		Intravenous Immunoglobulin	C	3	Yes	No
		Azathioprine	D	3	No	No
		Colchicine	D	3	No	No
		Thalidomide	D	3	Yes	Yes
		Mycophenolate mofetil	D	3	No	No
		Methotrexate	D	3	No	No
		Clofazimine	D	3	Yes	Yes
		Isotretinoin	E	3	No	No
		Anakinra	E	3	No	No
	Ustekinumab	E	3	No	No	
Raynaud disease (5 per 100) ¹⁸	Yes	CCB (i.e. nifedepine)	A	1	Yes	Yes
		Glyceryl trinitrate ¹⁹	A	1	No	No
		Psotacyclin analogs (i.e. iloprost)	A	1	No	No
		PDE-5 inhibitor (i.e. sildenafil)	A	1	Yes	No
		SSRI (i.e. fluoxetine)	B	2	Yes	No
		Bosentan	B	2	No	No
		Losartan	B	2	Yes	No
		Prazosin	A	2	Yes	Yes
		Alprostadil	B	3	Yes	No
		Dipyridamole	B	3	No	No
		Statins (i.e. atorvastatin)	A	3	No	No
	Rituximab	E	3	No	No	
Relapsing polychondritis (1 per 1,000,000 person-years) ²⁰	Yes	Colchicine	C	1	No	No
		Dapsone	C	1	Yes	No
		Azathioprine	D	2	No	No
		Cyclosporine	D	2	No	No
		Methotrexate	D	2	No	No
		Mycophenolate mofetil	D	2	No	No
		Leflunomide	D	2	No	No
		Cyclophosphamide	E	2	No	No
		Intravenous Immunoglobulin	E	2	No	No
			TNF inhibitors	D	2	No (E,A,I)

Sarcoidosis (5 per 100,000) ^{21,22}	Yes	Hydroxychloroquine	C	1	No	No
		Chloroquine	B	1	Yes	Yes
		Methotrexate	B	1	Yes	No
		Mycophenolate mofetil	D	2	No	No
		TNF inhibitors	B	2	Yes (E, A, I) - if ocular	No (E,A,I)
		Tetracycline-class antibiotics (e.g. doxycycline, minocycline)	D	2	No	No
		Thalidomide	D	3	Yes	Yes
		Allopurinol	D	3	No	Yes
		Isotretinoin	E	3	No	No
		Azathioprine	E	3	No	No
		Chlorambucil	B	3	Yes	Yes
		Quinacrine	D	3	No	No
		Pentoxifylline	E	3	No	No
		Apremilast	C	3	No	No
		Leflunomide	D	3	No	No
Dapsone	E	3	No	No		
Systemic sclerosis / Scleroderma (30 per 100,000) ²³	Yes	Nifedipine	A	1	No	Yes
		Iloprost	A	1	No	No
		Losartan	B	1	No	No
		Sildenafil	C	1	Yes	No
		Methotrexate	A	2	No	No
		Cyclophosphamide	B	2	Yes	No
		Acitretin	C	2	No	No
		Colchicine	C	2	No	No
		Mycophenolate mofetil	C	2	Yes	No
		Imatinib	B	3	Yes	No
		Cyclosporine	C	3	Yes	No
		Rituximab	C	3	No	No
		Etanercept	D	3	No	No

eReferences

1. Nguyen T, Razzaque Ahmed A. Autoimmune progesterone dermatitis: Update and insights. *Autoimmun Rev.* 2016;15(2):191-197.
2. Calamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM. Epidemiology and clinical characteristics of Behçet's disease in the US: a population-based study. *Arthritis Rheum.* 2009;61(5):600-604.
3. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJP, West J. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. *BMJ.* 2008;337:a180.
4. Jarukitsopa S, Hoganson DD, Crowson CS, et al. Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States. *Arthritis Care Res.* 2015;67(6):817-828.
5. Bernatsky S, Joseph L, Pineau CA, et al. Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. *Ann Rheum Dis.* 2009;68(7):1192-1196.
6. Spielmann L, Arnaud L, Severac F, et al. Population-based prevalence of eosinophilic fasciitis (Shulman syndrome): a capture-recapture study. *Br J Dermatol.* 2018;179(2):516-517.
7. Bernard P, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. *Arch Dermatol.* 1995;131(1):48-52.
8. Vañó-Galván S, Molina-Ruiz AM, Fernández-Crehuet P, et al. Folliculitis decalvans: a multicentre review of 82 patients. *J Eur Acad Dermatol Venereol JEADV.* 2015;29(9):1750-1757.
9. Muhlbauer JE. Granuloma annulare. *J Am Acad Dermatol.* 1980;3(3):217-230.
10. Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States. *JAMA Dermatol.* 2017;153(8):760-764.
11. Luo D-Q, Wu L-C, Liu J-H, Zhang H-Y. Acral persistent papular mucinosis: a case report and literature review. *J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG.* 2011;9(5):354-359.
12. Lings K, Bygum A. Linear IgA bullous dermatosis: a retrospective study of 23 patients in Denmark. *Acta Derm Venereol.* 2015;95(4):466-471.
13. Bertram F, Bröcker E-B, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. *J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG.* 2009;7(5):434-440.
14. Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. *BMJ Open.* 2015;5(1):e006450.
15. Griffiths WA. Pityriasis rubra pilaris. *Clin Exp Dermatol.* 1980;5(1):105-112.

16. Oh YJ, Lee M-H. Prurigo pigmentosa: a clinicopathologic study of 16 cases. *J Eur Acad Dermatol Venereol JEADV*. 2012;26(9):1149-1153.
17. Ashchyan HJ, Nelson CA, Stephen S, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses. Part II. Pyoderma gangrenosum and other bowel and arthritis associated neutrophilic dermatoses. *J Am Acad Dermatol*. April 2018.
18. Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France. *J Rheumatol*. 1993;20(1):70-76.
19. Overview. AHFS Drug Information. <http://www.ahfsdruginformation.com/off-label-uses-overview/>. Published April 8, 2016. Accessed October 30, 2018.
20. Hazra N, Dregan A, Charlton J, Gulliford MC, D'Cruz DP. Incidence and mortality of relapsing polychondritis in the UK: a population-based cohort study. *Rheumatol Oxf Engl*. 2015;54(12):2181-2187. doi:10.1093/rheumatology/kev240
21. Thomas KW, Hunninghake GW. Sarcoidosis. *JAMA*. 2003;289(24):3300-3303.
22. Marcoval J, Mañá J, Rubio M. Specific cutaneous lesions in patients with systemic sarcoidosis: relationship to severity and chronicity of disease. *Clin Exp Dermatol*. 2011;36(7):739-744.
23. Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. *Curr Opin Rheumatol*. 2012;24(2):165-170.